Edgewise Therapeutics, INC 10-Q quarterly reports

Edgewise Therapeutics details progress in cardiovascular pipeline and completion of sevasemten program sale, reporting a net loss of $57.3 million for Q2 2026.

Edgewise Therapeutics reported a wider net loss for Q1 2026 compared to the prior year, driven by increased research and development expenses.

Edgewise Therapeutics reported increased net losses in Q3 2025 and for the nine months ended September 30, 2025, driven by expanded research and development activities for its muscle disease pipeline, while maintaining a strong cash position.

Edgewise Therapeutics reported increased R&D expenses and net losses in Q2 2025, while maintaining a strong cash position of $594 million to fund operations for at least the next 12 months, driven by recent equity offerings and ongoing clinical trial advancements.

Edgewise Therapeutics reports a net loss of $40.8 million for Q1 2025, alongside updates on its clinical programs and financial position.

Edgewise Therapeutics reports a net loss of $34.1 million for Q3 2024, alongside updates on clinical trials and financial position.

Edgewise Therapeutics, a clinical-stage biopharmaceutical company, released its second quarter 2024 financial results, highlighting ongoing clinical trials and financial activities.

Edgewise Therapeutics reports a net loss of $28.5 million for the first quarter of 2024, alongside significant increases in marketable securities and research and development expenses.